Pharmaceuticals News and Research

RSS

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

Independent drugstore lobby demands more 'transparency' for PBMs in pharmacy supply chain

"Despite recent press revelations of its 'top secret' lobbying campaign to maintain the confidentiality of its own Medicaid pricing information, the independent drugstore lobby continues to demand more 'transparency' for others in the pharmacy supply chain, most notably PBMs.

30 Aug 2010

23rd ECNP Press conference on impact of circadian rhythms on human brain

All humans are synchronised to the rhythmic light-dark changes that occur on a daily basis. Rhythms in physiological and biochemical processes and behavioural patterns persist in the absence of all external 24-hour signals from the physical environment, with a period that is close to 24 hours

30 Aug 2010

Boehringer Ingelheim announces sub-analysis result of RE-LY trial

Boehringer Ingelheim today announced results from a pre-specified, retrospective, un-blinded sub-analysis of the RE-LY trial the largest atrial fibrillation outcomes trial ever conducted were published in The Lancet.

30 Aug 2010

Santarus extends line of credit agreement maturation date to July 2013

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has extended the maturity date of its $25 million revolving line of credit with Comerica Bank from July 11, 2011 to July 11, 2013.

30 Aug 2010

KIKA Clinical Solutions releases Veracity 3.10 Clinical Asset Management EDC platform

KIKA™ Clinical Solutions continues to drive EDC technology innovation with Veracity™ 3.10, the latest release of its market-leading, advanced EDC platform. KIKA is the leading provider of advanced EDC solutions for Clinical Asset Management™ for the pharmaceutical, biotechnology and medical device markets.

30 Aug 2010

Promising skin cancer drug in the near horizon

A new drug has been developed to combat a deadly form of skin cancer – melanoma. The drug, PLX4032, was tested on 32 melanoma patients who had a key mutation in their tumors. 26 of these patients responded favorably says the study published in the New England Journal of Medicine.

30 Aug 2010

MEND 7-13 Program improves obesity management in children

The MEND 7-13 Program today announced statistically significant results from 2009/2010 US Community Implementation Data. This preliminary data is the first to come from a US population and is further evidence that programs achieve positive outcomes and are welcomed by communities.

30 Aug 2010

ACOs to offer better coordinate care for patients

HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that provider groups in California, including physician groups, independent practice associations, hospitals and medical foundations, are beginning to shape their role in the anticipated shift towards accountable care organizations (ACO).

30 Aug 2010

Misuse of OTC medicines increases risk for children

Many children are being put at risk by parents over-use of widely available over the counter (OTC) medicines for fever, coughs and colds, says a study from Australia to be presented to the annual conference of the International Pharmaceutical Federation (FIP) today (Monday 30 August).

30 Aug 2010

Scientists report frog skin contains new genera of antibiotics

Kissing a frog won't turn it into a prince except in fairy tales but frogs may be hopping toward a real world transformation into princely allies in humanity's battle with antibiotic-resistant infections that threaten millions of people worldwide. Scientists today reported that frog skin contains natural substances that could be the basis for a powerful new genre of antibiotics.

30 Aug 2010

Authorities arrest more than 80 people, seize 10 tons of counterfeit meds in E. Africa

Authorities have arrested more than 80 people and seized 10 tons of counterfeit medicines across six East African countries, the international police agency Interpol announced Thursday, United Press International reports (8/26).

27 Aug 2010

Merck's initiation of IMO-2055 Phase 1b clinical trial in SCCHN triggers €3.0M milestone payment to Idera

Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).

27 Aug 2010

Fosun Pharma increases investment in Chindex

Chindex International, Inc., a leading independent American provider of Western healthcare products and services in the People's Republic of China, and Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a leading manufacturer and distributor of western and Chinese medicine and devices in China, today announced that they have consummated a previously-announced stock sale.

27 Aug 2010

Orexigen Therapeutics board approves grant of inducement stock options

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on August 25, 2010 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 10,000 shares of common stock to two new employees.

27 Aug 2010

FDA approves Novartis' Tekamlo for treatment of high blood pressure

The US Food and Drug Administration (FDA) approved Tekamlo™ (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren), with the widely used calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for patients whose blood pressure is not adequately controlled with either aliskiren or amlodipine alone.

27 Aug 2010

KemPharm broadens protection for LAT prodrug technology platform for ADHD with second patent

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same", U.S. Patent No. 7,776,917 B2. This patent, combined with KemPharm's recently issued U.S. Patent No. 7,772,222, provides broad protection of the Company's Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

27 Aug 2010

Shire receives European marketing approval for VPRIV therapy to treat type 1 Gaucher disease

Shire, the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease.

27 Aug 2010

Ricerca Biosciences completes purification of an API under cGMP controls

Ricerca Biosciences, a uniquely integrated preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, is pleased to announce the successful completion of the purification of an active pharmaceutical ingredient (API) under current good manufacturing practices (cGMP) controls.

27 Aug 2010

Wall Street Journal reports on pharma's growing interest in emerging markets

Abbott Laboratories will soon acquire the biggest share of India's pharmaceuticals market, about 7%, when the company closes as early as next month on a $3.7 billion takeover of the drugs business of Piramal Healthcare Ltd

27 Aug 2010